Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
LEGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$30.17 - $60.87
Previous CloseN/A
Volume249.07K
Average Volume (3M)1.14M
Market Cap
$6.79B
Enterprise Value$8.07B
Total Cash (Recent Filing)$286.75M
Total Debt (Recent Filing)$350.60M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
May 14, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding183,649,150
10 Day Avg. Volume1,082,790
30 Day Avg. Volume1,143,521
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.80
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit20.56
Enterprise Value/Ebitda-71.34
Forecast
1Y Price Target
$83.36Price Target Upside129.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Legend Biotech News
PremiumCompany Announcements
Legend Biotech’s Earnings Call: Growth and Expansion
---
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageCarvykti is currently the only CAR-T therapy with pivotal trials in front-line settings, giving it a competitive advantage over other CAR-T competitors.
Manufacturing ExpansionCarvykti's strong demand and manufacturing expansion are expected to drive significant sales growth in the coming year.
Market PositionCarvykti has gained significant share in 2-4L multiple myeloma treatments, making it a preferred therapy option.
Bears Say
Risk FactorsUnrestrained absolute leukocyte count is associated with higher ICANS/MNT, indicating a risk factor for parkinsonism.
Toxicity ConcernsCRS remains the most concerning toxicity for BCMA-CART therapies like Carvykti.
---
Ownership Overview
―
Insiders
15.17% Mutual Funds
22.92% Other Institutional Investors
59.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $30.17 and its highest was $60.87 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is $6.79B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is May 14, 2025 which is in 49 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on Mar 11, 2025. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of -$0.247 by $0.317.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is -0.21.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 183,649,150 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of $0.07 in its last earnings report, beating expectations of -$0.247. Following the earnings report the stock price went up 9.286%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in LEGN
---
Legend Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.36 (129.45% Upside)
$83.36 (129.45% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.51%
12-Months-Change
Fundamentals
Return on Equity
-15.45%
Trailing 12-Months
Asset Growth
-9.65%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
---
LEGN Company Deck
---
LEGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, market expansion, and improved financial performance for CARVYKTI. There were also significant advancements in manufacturing and pipeline development. However, some challenges remain, including supply constraints in Europe and ongoing efforts to address neurotoxicity. Overall, the positive aspects significantly outweigh the challenges.Read More>---
LEGN Stock 12 Month Forecast
Average Price Target
$83.36
▲(129.45% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Gilead Sciences
―
Vertex Pharmaceuticals
―
Bluebird Bio
―
Crispr Therapeutics AG
―
Best Analysts Covering LEGN
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
-5.33%
reiterated a buy rating 14 days ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -5.33% per trade.
---